PALVELLA THERAPEUTICS, INC.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
PVLA$168.71-3.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets at December 31, 2024 and 2023
CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share amounts)
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $83,602 | $7,350 |
| Accounts receivable | 358 | — |
| German research and development tax credit receivable | 1,978 | — |
| Prepaid expenses and other current assets | 2,296 | 198 |
| Total current assets | 88,234 | 7,548 |
| Total assets | $88,234 | $7,548 |
| LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) | ||
| Current liabilities: | ||
| Accounts payable | $4,586 | $936 |
| Derivative liabilities – contingent value right liability | 1,978 | — |
| Accrued expenses and other current liabilities | 5,474 | 1,424 |
| Total current liabilities | 12,038 | 2,360 |
| Royalty agreement liability | 11,942 | 8,054 |
| Derivative liabilities – royalty agreement | 1,647 | 1,014 |
| Total liabilities | 25,627 | 11,428 |
| Commitments and contingencies (Note 12) | ||
| Convertible preferred stock, $0.00001 par value; 0 and 20,655,895 shares authorized; 0 and 15,360,787 shares issued and outstanding at December 31, 2024 and 2023; aggregate liquidation value of $0 and $65,377 at December 31, 2024 and 2023 | — | 70,603 |
| Stockholders’ equity (deficit): | ||
| Preferred stock, $0.001; 10,000,000 shares authorized; 15,617 and 0 shares issued and outstanding at December 31, 2024 and 2023 | — | — |
| Common stock, $0.001; 200,000,000 shares authorized; 11,012,105 shares issued and outstanding at December 31, 2024. $0.00001 par value; 8,974,608 (7,891,466 voting and 1,083,142 non-voting) shares authorized; 1,770,167 (1,562,820 voting and 207,347 non-voting) shares issued and outstanding at December 31, 2023 | 11 | — |
| Additional paid-in capital | 156,328 | 1,818 |
| Accumulated other comprehensive income | 3 | — |
| Accumulated deficit | (93,735) | (76,301) |
| Total stockholders’ equity (deficit) | 62,607 | (74,483) |
| Total liabilities, convertible preferred stock and stockholders’ equity (deficit) | $88,234 | $7,548 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.